## David J Diemert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3731020/publications.pdf

Version: 2024-02-01

64 13,023 32 58
papers citations h-index g-index

69 69 69 20339 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine, 2021, 384, 403-416.	27.0	7,910
2	Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet, The, 2006, 367, 1521-1532.	13.7	1,981
3	Phase 1 Clinical Trial of Apical Membrane Antigen 1: an Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria. Infection and Immunity, 2005, 73, 3677-3685.	2.2	244
4	Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nature Reviews Microbiology, 2010, 8, 814-826.	28.6	236
5	Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine, 2005, 23, 3131-3138.	3.8	206
6	Hookworm infection. Nature Reviews Disease Primers, 2016, 2, 16088.	30.5	199
7	Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: Implications for the development of vaccines against helminths. Journal of Allergy and Clinical Immunology, 2012, 130, 169-176.e6.	2.9	151
8	Prevention and Self-Treatment of Traveler's Diarrhea. Clinical Microbiology Reviews, 2006, 19, 583-594.	13.6	118
9	The Global Economic and Health Burden of Human Hookworm Infection. PLoS Neglected Tropical Diseases, 2016, 10, e0004922.	3.0	111
10	Hookworm, <i>Ascaris lumbricoides</i> infection and polyparasitism associated with poor cognitive performance in Brazilian schoolchildren. Tropical Medicine and International Health, 2008, 13, 994-1004.	2.3	107
11	The Human Hookworm Vaccine. Vaccine, 2013, 31, B227-B232.	3.8	105
12	Hookworm Vaccines. Clinical Infectious Diseases, 2008, 46, 282-288.	5.8	95
13	Randomized, placebo-controlled, double-blind trial of the Na-ASP-2 Hookworm Vaccine in unexposed adults. Vaccine, 2008, 26, 2408-2417.	3.8	91
14	Age patterns in undernutrition and helminth infection in a rural area of Brazil: associations with ascariasis and hookworm. Tropical Medicine and International Health, 2008, 13, 458-467.	2.3	89
15	New technologies for the control of human hookworm infection. Trends in Parasitology, 2006, 22, 327-331.	3.3	84
16	Population structure of the genes encoding the polymorphic <i>Plasmodium falciparum</i> apical membrane antigen 1: Implications for vaccine design. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7857-7862.	7.1	83
17	Stage-specific immune responses in human Necator americanus infection. Parasite Immunology, 2007, 29, 347-358.	1.5	64
18	Safety and Allele-Specific Immunogenicity of a Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Trial. PLOS Clinical Trials, 2006, 1, e34.	3.5	64

#	Article	IF	CITATIONS
19	Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults. PLoS Neglected Tropical Diseases, 2017, 11, e0005574.	3.0	60
20	Comparison of Biological Activity of Human Anti-Apical Membrane Antigen-1 Antibodies Induced by Natural Infection and Vaccination. Journal of Immunology, 2008, 181, 8776-8783.	0.8	59
21	Confirmation by 16S rRNA PCR of the COBAS AMPLICOR CT/NG Test for Diagnosis of Neisseria gonorrhoeae Infection in a Low-Prevalence Population. Journal of Clinical Microbiology, 2002, 40, 4056-4059.	3.9	57
22	Impact of gender on the decision to participate in a clinical trial: a cross-sectional study. BMC Public Health, 2014, 14, 1156.	2.9	54
23	Impact of a Plasmodium falciparum AMA1 Vaccine on Antibody Responses in Adult Malians. PLoS ONE, 2007, 2, e1045.	2.5	53
24	Safety and immunogenicity of an ASO3-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS) Tj ETQ Lancet Infectious Diseases, The, 2022, 22, 636-648.	q0 0 0 rgB 9.1	T /Overlock : 52
25	Sputum Isolation of Wangiella dermatitidis in Patients with Cystic Fibrosis. Scandinavian Journal of Infectious Diseases, 2001, 33, 777-779.	1.5	47
26	Necator americanus and Helminth Co-Infections: Further Down-Modulation of Hookworm-Specific Type 1 Immune Responses. PLoS Neglected Tropical Diseases, 2011, 5, e1280.	3.0	41
27	Lessons along the Critical Path: Developing Vaccines against Human Helminths. Trends in Parasitology, 2018, 34, 747-758.	3.3	41
28	Advancing the Development of a Human Schistosomiasis Vaccine. Trends in Parasitology, 2019, 35, 104-108.	3.3	41
29	Rates and intensity of re-infection with human helminths after treatment and the influence of individual, household, and environmental factors in a Brazilian community. Parasitology, 2011, 138, 1406-1416.	1.5	40
30	A history of hookworm vaccine development. Hum Vaccin, 2011, 7, 1234-1244.	2.4	39
31	Controlled Human Hookworm Infection: Accelerating Human Hookworm Vaccine Development. Open Forum Infectious Diseases, 2018, 5, ofy083.	0.9	37
32	Molecular mechanisms of hookworm disease: Stealth, virulence, and vaccines. Journal of Allergy and Clinical Immunology, 2012, 130, 13-21.	2.9	34
33	Modeling the economic and epidemiologic impact of hookworm vaccine and mass drug administration (MDA) in Brazil, a high transmission setting. Vaccine, 2016, 34, 2197-2206.	3.8	33
34	Year-to-Year Variation in the Age-Specific Incidence of Clinical Malaria in Two Potential Vaccine Testing Sites in Mali With Different Levels of Malaria Transmission Intensity. American Journal of Tropical Medicine and Hygiene, 2007, 77, 1028-1033.	1.4	31
35	Potency testing for the experimental <i>Na</i> -GST-1 hookworm vaccine. Expert Review of Vaccines, 2010, 9, 1219-1230.	4.4	29
36	Human challenge trials in vaccine development, Rockville, MD, USA, September 28–30, 2017. Biologicals, 2019, 61, 85-94.	1.4	29

#	Article	IF	Citations
37	Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial. Lancet Infectious Diseases, The, 2021, 21, 275-285.	9.1	27
38	The Right Tool for the Job: Detection of Soil-Transmitted Helminths in Areas Co-endemic for Other Helminths. PLoS Neglected Tropical Diseases, 2015, 9, e0003967.	3.0	26
39	Microproteinuria during Opisthorchis viverrini Infection: A Biomarker for Advanced Renal and Hepatobiliary Pathologies from Chronic Opisthorchiasis. PLoS Neglected Tropical Diseases, 2013, 7, e2228.	3.0	25
40	Year-to-year variation in the age-specific incidence of clinical malaria in two potential vaccine testing sites in Mali with different levels of malaria transmission intensity. American Journal of Tropical Medicine and Hygiene, 2007, 77, 1028-33.	1.4	25
41	An ounce of prevention on a budget: a nonprofit approach to developing vaccines against neglected diseases. Expert Review of Vaccines, 2006, 5, 189-198.	4.4	21
42	Serum <scp>CCL</scp> 11 (eotaxinâ€1) and <scp>CCL</scp> 17 ( <scp>TARC</scp> ) are serological indicators of multiple helminth infections and are driven by <i>Schistosoma mansoni</i> infection in humans. Tropical Medicine and International Health, 2013, 18, 750-760.	2.3	20
43	Malaria "epidemic" in Quebec: diagnosis and response to imported malaria. Cmaj, 2005, 172, 46-50.	2.0	18
44	Health Education through Analogies: Preparation of a Community for Clinical Trials of a Vaccine against Hookworm in an Endemic Area of Brazil. PLoS Neglected Tropical Diseases, 2010, 4, e749.	3.0	18
45	A pesquisa cientÃfica na saúde: uma análise sobre a participação de populações vulneráveis. Texto E Contexto Enfermagem, 2010, 19, 104-111.	0.4	12
46	Selection and quantification of infection endpoints for trials of vaccines against intestinal helminths. Vaccine, 2011, 29, 3686-3694.	3.8	12
47	Improving the understanding of schistosomiasis among adolescents in endemic areas in Brazil: A comparison of educational methods. Patient Education and Counseling, 2016, 99, 1657-1662.	2.2	12
48	A Comparison of the Quality of Informed Consent for Clinical Trials of an Experimental Hookworm Vaccine Conducted in Developed and Developing Countries. PLoS Neglected Tropical Diseases, 2017, 11, e0005327.	3.0	12
49	Advances in neglected tropical disease vaccines: Developing relative potency and functional assays for the Na-GST-1/Alhydrogel hookworm vaccine. PLoS Neglected Tropical Diseases, 2017, 11, e0005385.	3.0	12
50	Can schistosomiasis really be consigned to history without a vaccine?. Vaccine, 2008, 26, 3373-3376.	3.8	10
51	Update on Prevention and Treatment of Intestinal Helminth Infections. Current Infectious Disease Reports, 2015, 17, 465.	3.0	9
52	Prevention and self-treatment of travelers' diarrhea. Primary Care - Clinics in Office Practice, 2002, 29, 843-855.	1.6	7
53	Characterization of T cell responses to co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in healthy adults in Gabon. PLoS Neglected Tropical Diseases, 2021, 15, e0009732.	3.0	6
54	Differences in the Platelet mRNA Landscape Portend Racial Disparities in Platelet Function and Suggest Novel Therapeutic Targets. Clinical Pharmacology and Therapeutics, 2021, 110, 702-713.	4.7	5

#	Article	IF	CITATIONS
55	Controlled Infection of Humans with the Hookworm Parasite Necator americanus to Accelerate Vaccine Development. Current Topics in Microbiology and Immunology, 2021, , 1.	1.1	4
56	Ascariasis., 2011,, 794-798.		3
57	Potency testing for a recombinant protein vaccine early in clinical development: Lessons from the Schistosoma mansoni Tetraspanin 2 vaccine. Vaccine: X, 2021, 8, 100100.	2.1	3
58	Parasitic helminth infections in humans modulate Trefoil Factor levels in a manner dependent on the species of parasite and age of the host. PLoS Neglected Tropical Diseases, 2021, 15, e0009550.	3.0	2
59	Hookworm Infection. , 2009, , 1365-1378.		1
60	Tissue Nematode Infections. , 2012, , 2069-2076.		1
61	Intestinal Nematode Infections. , 2012, , 2064-2068.		1
62	"Emerging―Neglected Tropical Diseases. , 0, , 273-285.		1
63	Debate: Letter to the Editors. Tropical Medicine and International Health, 2007, 12, 470-471.	2.3	0
64	Cestode and trematode infections. , 2010, , 1177-1181.		0